ReviewJournal of translational medicine2019
New paradigm for stage III melanoma: from surgery to adjuvant treatment.
Review in Journal of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Sentinel Node Biopsy for Head and Neck Melanoma: A 12-Year Experience from a Medium-Volume Regional Center.Journal of clinical medicine · 2026Article
- Case Report: The role of BRAF mutation in adjuvant and neoadjuvant treatment of melanoma patients: what is the optimal approach?Frontiers in oncology · 2026Article
- Rethinking Lymphadenectomy in Cutaneous Melanoma: From Routine Practice to Selective Indication: A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US.BMC cancer · 2024Article
- Isolated melanoma metastasis in a patient with large congenital nevus without detectable primary melanoma: a case report and review of literature.Frontiers in medicine · 2024Article
- Article
- Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field.Cancers · 2023Review
- Article
- A deep learning model based on whole slide images to predict disease-free survival in cutaneous melanoma patients.Scientific reports · 2022Article
- Clinical Significance of Distant Metastasis-Free Survival (DMFS) in Melanoma: A Narrative Review from Adjuvant Clinical Trials.Journal of clinical medicine · 2021Review
- Head and neck melanoma: outcome and predictors in a population-based cohort study.Head & face medicine · 2021Article
- Primary Melanoma Characteristics of Metastatic Disease: A Nationwide Cancer Registry Study.Cancers · 2021Article
- The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges.Targeted oncology · 2021Review
- Review
- Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.The British journal of dermatology · 2021Article
- Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Management of the positive sentinel lymph node in the post-MSLT-II era.Journal of surgical oncology · 2020Article
- Selective, high-contrast detection of syngeneic glioblastoma in vivo.Scientific reports · 2020Article
- Correction to: New paradigm for stage III melanoma: from surgery to adjuvant treatment.Journal of translational medicine · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecently the 8th version of the American Joint Committee on Cancer (AJCC) classification has been introduced, and has attempted to define a more accurate and precise definition of prognosis in line with the major progresses in understanding the biology and pathogenesis of melanoma. This new staging system introduces major changes in the stage III staging system. Indeed, surgical practice is changing in stage III patients, since, according to recent evidence, there is no survival benefit in radical lymph node dissection following a positive sentinel lymph node dissection. Therefore, some patients currently staged IIIB-C after dissection could be downgraded to IIIA (as in the case of patients with metastatic non-sentinel lymph nodes) since many completion lymph node dissections will no longer be performed. Moreover, new and effective targeted and immune strategies are being introduced in the pharmacological armamentarium in the adjuvant setting, showing major efficacy.
conclusionsThis article provides the authors' personal view on the above-mentioned topics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.